Latest Conference Articles

September 12th 2017, 10:16pm

ESMO Congress

Although second-line treatment with combined pazopanib and gemcitabine demonstrated disease control in the majority of patients with metastatic or relapsed uterine or soft tissue leiomyosarcomas, the phase II UNICANCER SARCOME 11 study did not meet statistical endpoints and is considered a negative trial.

September 12th 2017, 8:35pm

ESMO Congress: GU Cancers

Treating primary tumors by administering targeted therapy with sunitinib (Sutent) prior to cytoreductive nephrectomy did not improve the progression-free rate at 28 weeks over a sequence of immediate CN followed by sunitinib in patients with synchronous metastatic renal cell carcinoma.

September 12th 2017, 4:53pm

ESMO Congress

Nivolumab (Opdivo) may represent a new standard option for adjuvant therapy for patients with resected stage IIIB/C and IV melanoma, whether or not they have a BRAF mutation. In a comparison with current standard high-dose ipilimumab (Yervoy), nivolumab demonstrated a significant improvement in relapse-free survival.

September 11th 2017, 11:46pm

ESMO Congress: GU Cancers

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) was superior to sunitinib (Sutent) monotherapy as first-line treatment of advanced or metastatic renal cell carcinoma.

September 11th 2017, 11:13pm

ESMO Congress

Omid Hamid, MD, director of the melanoma center at the Angeles Clinic & Research Institute in Los Angeles, discusses the phase III results of the ECHO-202/KEYNOTE-037 trial, which explored the IDO inhibitor epacadostat plus pembrolizumab (Keytruda) in patients with advanced melanoma.

September 11th 2017, 9:43pm

ESMO Congress: GU Cancers

Ramucirumab (Cyramza) plus docetaxel improved progression-free survival over docetaxel alone in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy.

September 11th 2017, 9:29pm

ESMO Congress

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the CheckMate-238 trial for patients with melanoma.

September 11th 2017, 9:29pm

ESMO Congress: Lung Cancer

Solange Peters, MD, PhD, head of the Thoracic Malignancies Program in the Department of Oncology at the University of Lausanne in Switzerland, discusses the FLAURA trial for patients with EGFR-mutated non

September 11th 2017, 8:58pm

ESMO Congress: GU Cancers

Patients with untreated advanced renal cell carcinoma lived significantly longer without disease progression when they received the multikinase inhibitor cabozantinib (Cabometyx) as initial therapy versus sunitinib (Sutent).

September 11th 2017, 6:39pm

ESMO Congress: GU Cancers

Lenvatinib (Lenvima) combined with pembrolizumab (Keytruda) demonstrated promising antitumor activity in patients with metastatic clear cell renal cell carcinoma.

September 11th 2017, 4:55pm

ESMO Congress: GU Cancers

Atezolizumab with bevacizumab provided improved progression-free survival over sunitinib in patients with untreated metastatic renal cell carcinoma.

September 11th 2017, 3:59pm

ESMO Congress: Lung Cancer

Frontline treatment with the combination of dabrafenib and trametinib showed promising clinical efficacy for patients with BRAF-mutant metastatic non–small cell lung cancer.

September 11th 2017, 11:17am

ESMO Congress

Adjuvant treatment with dabrafenib and trametinib reduced the risk of relapse or death by 53% compared with placebo for patients with stage III BRAF-mutant melanoma.

September 10th 2017, 10:20pm

ESMO Congress: GU Cancers

Mature results from the phase III KEYNOTE-045 study presented at the 2017 ESMO Congress demonstrated that overall survival with pembrolizumab (Keytruda) continued to improve compared to chemotherapy in patients with recurrent, advanced urothelial carcinoma.

September 10th 2017, 9:52pm

ESMO Congress: Gynecologic Cancers

Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, and medical director of the Nordic Society of Gynecologic Oncology-Clinical Trial Unit, discusses phase I results of a trial exploring the combination of niraparib (Zejula) and bevacizumab (Avastin) in patients with platinum-sensitive epithelial ovarian cancer.

September 10th 2017, 9:05pm

ESMO Congress: GU Cancers

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the significance of the phase II CABOSUN trial, which explored cabozantinib (Cabometyx) as a frontline therapy for patients with renal cell carcinoma (RCC).

September 10th 2017, 8:36pm

ESMO Congress: Lung Cancer

Expanding surveillance after surgery for early-stage non–small cell lung cancer from chest x-ray to follow-up with PET-CT scan did not improve overall survival.

September 10th 2017, 6:04pm

ESMO Congress

A majority of patients with advanced melanoma responded to the combination of pembrolizumab and the investigational IDO1 inhibitor epacadostat.

September 10th 2017, 10:37am

ESMO Congress: Breast Cancer

The addition of abemaciclib to anastrozole or letrozole reduced the risk of progression or death by 46% compared with the non-steroidal aromatase inhibitors alone for previously untreated patients with HER2-negative, HR-positive advanced breast cancer.

September 9th 2017, 10:21pm

ESMO Congress

More than one-third of patients with resectable giant cell tumor of bone avoided surgery and nearly half had less morbidity with surgery when treated with denosumab (Xgeva).